The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?

Hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Disease Primers

Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma

(2020) Bruno Sangro et al.   JOURNAL OF HEPATOLOGY

Advances in molecular classification and precision oncology in hepatocellular carcinoma

(2020) Sandra Rebouissou et al.   JOURNAL OF HEPATOLOGY

Sequential systemic treatment in patients with hepatocellular carcinoma

(2020) Martha M. Kirstein et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer

(2020) Yoon-Koo Kang et al.   CLINICAL CANCER RESEARCH

Genetics of HCC: Novel approaches to explore molecular diversity

(2020) Stefano Caruso et al.   HEPATOLOGY

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

(2020) Luis Paz-Ares et al.   Journal of Thoracic Oncology

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety‐Assessment Cohort

(2020) Toshihiko Doi et al.   ONCOLOGIST

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib

(2020) Gianluigi Giannelli et al.   PLoS One

Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival

(2020) SiZhe Yu et al.   PLoS One

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

(2020) Constance J. Martin et al.   Science Translational Medicine

Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors

(2020) Federico Piñero et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

(2020) Changhoon Yoo et al.   Journal for ImmunoTherapy of Cancer

Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma

(2020) Min Zhang et al.   JOURNAL OF HEPATOLOGY

Hepatic Stellate Cells and Hepatocarcinogenesis

(2020) Anna E. Barry et al.   Frontiers in Cell and Developmental Biology

A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma

(2020) Kim A. Reiss et al.   MOLECULAR CANCER THERAPEUTICS

Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts

(2020) Xueke Shi et al.   Biomolecules

Recent progress in TGF-β inhibitors for cancer therapy

(2020) Cheng-Yi Huang et al.   BIOMEDICINE & PHARMACOTHERAPY

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Andrew X Zhu et al.   LANCET ONCOLOGY

α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

(2019) E. Dodagatta-Marri et al.   Journal for ImmunoTherapy of Cancer

Specificity, versatility, and control of TGF-β family signaling

(2019) Rik Derynck et al.   Science Signaling

Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib

(2019) Álvaro Díaz-González et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells

(2019) Ming Zhong et al.   BMC CANCER

Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib ( LY 2157299) in Advanced Hepatocellular Carcinoma

(2019) Sandrine Faivre et al.   LIVER INTERNATIONAL

LXRα limits TGFβ-dependent hepatocellular carcinoma associated fibroblast differentiation

(2019) Anita Morén et al.   Oncogenesis

Insights into the success and failure of systemic therapy for hepatocellular carcinoma

(2019) Jordi Bruix et al.   Nature Reviews Gastroenterology & Hepatology

Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma

(2019) Jian Chen et al.   TRENDS IN MOLECULAR MEDICINE

Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts

(2019) Ela Elyada et al.   Cancer Discovery

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

(2019) R.K. Kelley et al.   Clinical and Translational Gastroenterology

TGF-β signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond syndrome

(2019) Cailin E. Joyce et al.   JOURNAL OF CLINICAL INVESTIGATION

Clathrin switches Transforming Growth Factor-β role to pro-tumorigenic in liver cancer

(2019) Daniel Caballero-Díaz et al.   JOURNAL OF HEPATOLOGY

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

(2019) T Yau et al.   ANNALS OF ONCOLOGY

TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019

(2019) Dewidar et al.   Cells

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway

(2018) Jian Chen et al.   GASTROENTEROLOGY

Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cells

(2018) Jun Arai et al.   INTERNATIONAL JOURNAL OF CANCER

A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma

(2018) Masafumi Ikeda et al.   INVESTIGATIONAL NEW DRUGS

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Contextual determinants of TGFβ action in development, immunity and cancer

(2018) Charles J. David et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

(2018) Yan Lan et al.   Science Translational Medicine

Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression

(2018) Bhavna Rani et al.   Cell Death & Disease

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

(2018) Rajani Ravi et al.   Nature Communications

CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128

(2018) Mohamed Badawi et al.   Oncotarget

IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction

(2018) Nicholas J. W. Easom et al.   Frontiers in Immunology

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

(2018) Rikke B. Holmgaard et al.   Journal for ImmunoTherapy of Cancer

CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma

(2018) Long-Zi Liu et al.   HEPATOLOGY

Neutrophils Promote Amphiregulin Production in Intestinal Epithelial Cells through TGF-β and Contribute to Intestinal Homeostasis

(2018) Feidi Chen et al.   JOURNAL OF IMMUNOLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis

(2018) Isabel Fabregat et al.   Frontiers in Oncology

TGF-β as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives

(2018) Serena Mancarella et al.   SEMINARS IN LIVER DISEASE

CD4+ CD25+ regulatory T cells promote hepatocellular carcinoma invasion via TGF-β1-induced epithelial–mesenchymal transition

(2018) Chunying Shi et al.   OncoTargets and Therapy

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features

(2017) Daniela Sia et al.   GASTROENTEROLOGY

iNKT Cells Orchestrate a Switch from Inflammation to Resolution of Sterile Liver Injury

(2017) Pei Xiong Liew et al.   IMMUNITY

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer

(2017) Daniel Öhlund et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8

(2017) Julie Stockis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transforming Growth Factor-β Receptors and Smads: Regulatory Complexity and Functional Versatility

(2017) Erine H. Budi et al.   TRENDS IN CELL BIOLOGY

NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC

(2017) Yuan Cao et al.   Cell Death & Disease

Vascular mimicry formation is promoted by paracrine TGF-β and SDF1 of cancer-associated fibroblasts and inhibited by miR-101 in hepatocellular carcinoma

(2016) Jine Yang et al.   CANCER LETTERS

Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-β pathways

(2016) Jiao Liu et al.   CANCER LETTERS

Stimulation of Natural Killer Cell–Mediated Tumor Immunity by an IL15/TGFβ–Neutralizing Fusion Protein

(2016) Spencer Ng et al.   CANCER RESEARCH

The role of integrins in TGFβ activation in the tumour stroma

(2016) Zareen Khan et al.   CELL AND TISSUE RESEARCH

The rationale for targeting TGF-β in chronic liver diseases

(2016) Gianluigi Giannelli et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

TGF-β signalling and liver disease

(2016) Isabel Fabregat et al.   FEBS Journal

Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis

(2016) Sihua Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells

(2016) Nathan Ungerleider et al.   MOLECULAR CARCINOGENESIS

TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway

(2016) Sébastien Viel et al.   Science Signaling

The Discovery and Early Days of TGF-β: A Historical Perspective

(2016) Harold L. Moses et al.   Cold Spring Harbor Perspectives in Biology

TGF 1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer

(2016) B. V. Park et al.   Cancer Discovery

A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands

(2016) Tai Qin et al.   Oncotarget

TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway

(2016) Sébastien Viel et al.   Science Signaling

Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC

(2016) A. Gabrielson et al.   Cancer Immunology Research

TGF-β Regulates Hepatocellular Carcinoma Progression by Inducing Treg Cell Polarization

(2015) Yinan Shen et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma

(2015) Teng Feng et al.   CLINICAL SCIENCE

Transforming growth factor-β1 regulates human renal proximal tubular epithelial cell susceptibility to natural killer cells via modulation of the NKG2D ligands

(2015) HYUNKEUN SONG et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver

(2015) Monika Rau et al.   JOURNAL OF IMMUNOLOGY

Mesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor β1

(2015) GUO-CAI LI et al.   Oncology Letters

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

(2015) Michael Lahn et al.   Drug Design Development and Therapy

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients

(2015) Maria Serova et al.   Oncotarget

TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling

(2015) Sang-A Park et al.   Scientific Reports

Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress

(2015) Meriem Hasmim et al.   Frontiers in Immunology

TGF-β-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells

(2014) Antonella Carambia et al.   JOURNAL OF HEPATOLOGY

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib

(2014) Maria Reig et al.   JOURNAL OF HEPATOLOGY

Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

(2014) John C. Morris et al.   PLoS One

Inhibition of TGF-β/SMAD3/NF-κB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells

(2014) Fei Jiang et al.   TOXICOLOGY LETTERS

Caveolin-1 is required for TGF- β -induced transactivation of the EGF receptor pathway in hepatocytes through the activation of the metalloprotease TACE/ADAM17

(2014) J Moreno-Càceres et al.   Cell Death & Disease

Transforming growth factor β induces expression of connective tissue growth factor in hepatic progenitor cells through Smad independent signaling

(2013) Ze-yang Ding et al.   CELLULAR SIGNALLING

Unchaining the beast; insights from structural and evolutionary studies on TGFβ secretion, sequestration, and activation

(2013) Ian B. Robertson et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells

(2013) Esther Bertran et al.   HEPATOLOGY

Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice

(2013) Ling Yang et al.   HEPATOLOGY

Amphiregulin Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor Receptor

(2013) Dietmar M.W. Zaiss et al.   IMMUNITY

Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer

(2013) Gabriela Bindea et al.   IMMUNITY

Inactivation of tumor-specific CD8+ CTLs by tumor-infiltrating tolerogenic dendritic cells

(2013) Hirotomo Harimoto et al.   IMMUNOLOGY AND CELL BIOLOGY

NANOG promotes liver cancer cell invasion by inducing epithelial–mesenchymal transition through NODAL/SMAD3 signaling pathway

(2013) Chun Sun et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Transforming Growth Factor-β (TGF-β)-mediated Connective Tissue Growth Factor (CTGF) Expression in Hepatic Stellate Cells Requires Stat3 Signaling Activation

(2013) Yan Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells

(2013) Chia-Lin Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune surveillance by the liver

(2013) Craig N Jenne et al.   NATURE IMMUNOLOGY

Comparative Analysis of TGF-β/Smad Signaling Dependent Cytostasis in Human Hepatocellular Carcinoma Cell Lines

(2013) Johanna Dzieran et al.   PLoS One

Correction: Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II

(2013) Francesco Dituri et al.   PLoS One

Combination of Intratumoral Invariant Natural Killer T Cells and Interferon-Gamma Is Associated with Prognosis of Hepatocellular Carcinoma after Curative Resection

(2013) Yong-Sheng Xiao et al.   PLoS One

Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology

(2013) Ingmar Mederacke et al.   Nature Communications

TGF-  Signaling in Myeloid Cells Is Required for Tumor Metastasis

(2013) Y. Pang et al.   Cancer Discovery

Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

(2013) James P Stevenson et al.   OncoImmunology

Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions

(2012) J. L. Espinoza et al.   HAEMATOLOGICA

Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions

(2012) Yan Wu et al.   HEPATOLOGY

Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: A crucial role of CD25−FOXP3−T cells

(2012) Naruyasu Kakita et al.   INTERNATIONAL JOURNAL OF CANCER

Engineering and Therapeutic Application of Single-Chain Bivalent TGF-  Family Traps

(2012) J. C. Zwaagstra et al.   MOLECULAR CANCER THERAPEUTICS

The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-β and suppresses TH2 differentiation

(2012) Makoto Kuwahara et al.   NATURE IMMUNOLOGY

Targeting the TGFβ signalling pathway in disease

(2012) Rosemary J. Akhurst et al.   NATURE REVIEWS DRUG DISCOVERY

Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma

(2012) Elisabetta Cariani et al.   PLoS One

NADPH Oxidase NOX4 Mediates Stellate Cell Activation and Hepatocyte Cell Death during Liver Fibrosis Development

(2012) Patricia Sancho et al.   PLoS One

TGF-β in progression of liver disease

(2011) Steven Dooley et al.   CELL AND TISSUE RESEARCH

Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases

(2011) Jeffrey L. Barnes et al.   KIDNEY INTERNATIONAL

Anti-Transforming Growth Factor ß Antibody Treatment Rescues Bone Loss and Prevents Breast Cancer Metastasis to Bone

(2011) Swati Biswas et al.   PLoS One

Cancer-related inflammation: Common themes and therapeutic opportunities

(2011) Frances R. Balkwill et al.   SEMINARS IN CANCER BIOLOGY

Anti-Transforming Growth Factor   Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

(2010) Z. Zhong et al.   CLINICAL CANCER RESEARCH

Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects

(2010) W. Zhang et al.   CLINICAL CANCER RESEARCH

Dissecting the effect of targeting the epidermal growth factor receptor on TGF-β-induced-apoptosis in human hepatocellular carcinoma cells

(2010) Laia Caja et al.   JOURNAL OF HEPATOLOGY

Synergistic Enhancement of CD8+ T Cell-Mediated Tumor Vaccine Efficacy by an Anti-Transforming Growth Factor-  Monoclonal Antibody

(2009) M. Terabe et al.   CLINICAL CANCER RESEARCH

Cell-Intrinsic Transforming Growth Factor-β Signaling Mediates Virus-Specific CD8+ T Cell Deletion and Viral Persistence In Vivo

(2009) Roberto Tinoco et al.   IMMUNITY

iNKT cell development is orchestrated by different branches of TGF-β signaling

(2009) Jean-Marc Doisne et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Transforming Growth Factor- 1 and CD105 Promote the Migration of Hepatocellular Carcinoma-Derived Endothelium

(2008) A. Benetti et al.   CANCER RESEARCH

An Anti-Transforming Growth Factor   Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments

(2008) J.-S. Nam et al.   CANCER RESEARCH

Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer

(2008) Cédric Coulouarn et al.   HEPATOLOGY

Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity

(2008) Irene Carmona-Cuenca et al.   JOURNAL OF HEPATOLOGY

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

(2007) Lorea Bueno et al.   EUROPEAN JOURNAL OF CANCER